Eloxx Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Eloxx Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eloxx Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eloxx Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
View up-to-date information on Eloxx Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| AU2021203691B2 | Grant | Aminoglycoside derivatives and uses thereof in treating genetic disorders | A61P13/12; A61P17/00; A61P21/00; A61P21/04; A61P27/02; A61P35/00; A61P43/00; A61P7/04; C07H15/222; C07H15/224; C07H15/23 | February 23, 2023 |
| JP7187471B2 | Grant | 擬似三糖アミノグリコシドおよびその中間体の大規模調製 | C07H1/00; C07H13/12; C07H15/224; C07H15/23 | December 12, 2022 |
| WO2022251730A1 | Application | COMPOUNDS FOR TREATING GENETIC DISEASES | A61K31/7052; A61K45/06; A61P11/00; A61P17/00; C07H17/08 | December 01, 2022 |
| AU2022256098A1 | Application | Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof | C07H1/00; C07H13/12; C07H15/224; C07H15/23 | November 17, 2022 |
| IL295474A | Application | Aminoglycoside derivatives and uses thereof in treating genetic disorders | A61K31/7036; A61P13/12; A61P17/00; A61P21/00; A61P21/04; A61P27/02; A61P35/00; A61P43/00; A61P7/04; C07D309/10; C07D407/12; C07H15/222; C07H15/224; C07H15/23 | October 01, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer